# Temozolomide in Treating Patients With Invasive Pituitary Tumors

> **NCT00601289** · PHASE2 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** temozolomide
- **GENETIC:** DNA methylation analysis
- **GENETIC:** microarray analysis
- **GENETIC:** protein expression analysis
- **GENETIC:** proteomic profiling
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00601289
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-12
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** funding term ended
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00601289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00601289, "Temozolomide in Treating Patients With Invasive Pituitary Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00601289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*